Resectable Hepatocellular Carcinoma

19 clinical trials · Condition

Record	Firm	Date
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer (NCT04965714)	M.D. Anderson Cancer Center	2022-04-13
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant (NCT02379377)	M.D. Anderson Cancer Center	2022-02-15
Surgical Resection for Hepatocellular Carcinoma (NCT06013657)	Dr Cipto Mangunkusumo General Hospital	2021-12-01
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer (NCT04856046)	Mayo Clinic	2021-11-06
SBRT + Atezolizumab + Bevacizumab in Resectable HCC (NCT04857684)	Massachusetts General Hospital	2021-06-18
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (NCT04834986)	Tianjin Medical University Cancer Institute and Hospital	2021-04-30
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer (NCT04721132)	M.D. Anderson Cancer Center	2021-02-10
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (NCT04701060)	Tianjin Medical University Cancer Institute and Hospital	2021-01-26
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer (NCT03222076)	M.D. Anderson Cancer Center	2017-09-28
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820)	Roswell Park Cancer Institute	2012-03-01

Every clearance here is in the API, with alerts when new ones post.